Drugs / IXP
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06529796 | Aug → Dec 2024 | focal segmental glomerulosclerosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IXP | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06529796 ↗ |
| Route | Oral | “Tablet for oral administration.” NCT06529796 ↗ |